Highly potent, fully recombinant anti-HIV chemokines: Reengineering a low-cost microbicide
暂无分享,去创建一个
R. Offord | F. Cerini | H. Gaertner | D. Mosier | O. Hartley | R. Nedellec | Irène Rossitto-Borlat | G. Gorochov | J. Salkowitz | A. Melotti | J. Escola | G. Kuenzi
[1] S. Ferguson,et al. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. , 2001, Pharmacological reviews.
[2] Natasha Bolognesi. AIDS gel's failure calls prevention approach into question , 2007, Nature Medicine.
[3] John P. Moore. Topical microbicides become topical. , 2005, The New England journal of medicine.
[4] Marc Parmentier,et al. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. , 2002, Molecular biology of the cell.
[5] E. Arts,et al. PSC-RANTES Blocks R5 Human Immunodeficiency Virus Infection of Langerhans Cells Isolated from Individuals with a Variety of CCR5 Diplotypes , 2004, Journal of Virology.
[6] HIV vaccine failure prompts Merck to halt trial , 2007, Nature.
[7] Jean Salamero,et al. HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.
[8] A. Trkola,et al. RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. , 2003, Blood.
[9] Oliver Hartley,et al. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[10] G. Abraham,et al. Pyroglutamic acid , 1981, Molecular and Cellular Biochemistry.
[11] O. Hartley,et al. Targeting chemokine receptors in HIV: a status report. , 2008, Annual review of pharmacology and toxicology.
[12] M. Lederman,et al. Microbicides and other topical strategies to prevent vaginal transmission of HIV , 2006, Nature Reviews Immunology.
[13] Nancy Sullivan,et al. CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro , 1997, The Journal of experimental medicine.
[14] A. Trkola,et al. Genetic Subtype-Independent Inhibition of Human Immunodeficiency Virus Type 1 Replication by CC and CXC Chemokines , 1998, Journal of Virology.
[15] J. Church. Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5 , 2005, Pediatrics.
[16] R. Offord,et al. Semisynthetic analogues of PSC-RANTES, a potent anti-HIV protein. , 2008, Bioconjugate chemistry.
[17] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[18] Jens V Stein,et al. How chemokines invite leukocytes to dance , 2008, Nature Immunology.
[19] M. Parmentier,et al. Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4. , 2008, Protein engineering, design & selection : PEDS.
[20] P. Debré,et al. Human Immunodeficiency Virus Type 1 Entry Inhibitors Selected on Living Cells from a Library of Phage Chemokines , 2003, Journal of Virology.
[21] O. Chaloin,et al. Donor- and Ligand-Dependent Differences in C-C Chemokine Receptor 5 Reexpression , 2001, Journal of Virology.
[22] John P. Moore,et al. Which Topical Microbicides for Blocking HIV-1 Transmission Will Work in the Real World? , 2006, PLoS medicine.
[23] M. Oppermann,et al. Differential Effects of CC Chemokines on CC Chemokine Receptor 5 (CCR5) Phosphorylation and Identification of Phosphorylation Sites on the CCR5 Carboxyl Terminus* , 1999, The Journal of Biological Chemistry.
[24] Myron S. Cohen,et al. The role of sexually transmitted diseases in HIV transmission , 2004, Nature Reviews Microbiology.
[25] M. Thelen,et al. Dancing to the tune of chemokines , 2001, Nature Immunology.
[26] P. Skagerlind,et al. Industrial enzymes. , 2007, Advances in biochemical engineering/biotechnology.
[27] Jon Cohen. Microbicide Fails to Protect Against HIV , 2008, Science.
[28] John P. Moore,et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion , 2005, Nature.
[29] P. Lusso,et al. Rational design of novel HIV-1 entry inhibitors by RANTES engineering. , 2008, Vaccine.
[30] F. Galimi,et al. Two Mechanisms for Human Immunodeficiency Virus Type 1 Inhibition by N-Terminal Modifications of RANTES , 2003, Antimicrobial Agents and Chemotherapy.
[31] Terry Kenakin,et al. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. , 2007, Trends in pharmacological sciences.
[32] R. Offord,et al. Engineering chemokines to develop optimized HIV inhibitors. , 2005, Current protein & peptide science.
[33] Brandon Keim. Canceled conference puts conflicts of interest under scrutiny , 2007, Nature Medicine.
[34] S. Kent. Novel forms of chemical protein diversity -- in nature and in the laboratory. , 2004, Current opinion in biotechnology.